Skip to main content

Recent News

  • RheumNow Podcast square

    Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcastL hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis.

    Read Article
Dr. John Cush
@RheumNow
Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings Listen to leading rheumatology and dermatology experts for an engaging discussion on the evolving landscape of Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE). https://t.co/lJOzeR81AS
Dr. John Cush
@RheumNow
The Efficacy of Ianalumab in Sjögren’s Disease The NEPTUNUS-1 and NEPTUNUS-2 trials have showed that monthly ianalumab is superior of placebo at improving Sjögren’s disease activity at week 48, even though there was no significant ESSDAI response or in the change in SSSD or https://t.co/YStzIFq5Bx
Dr. John Cush
@RheumNow
Tx persistence & response in PsA is a problem - influenced by demographics & Dz severity. 815 PsA pts in e Brit Society Rheumatology PsA Registe. @12 mos - 24% MDA, 24% ACR50. Median F/U 31 mos, only 65% still on index Rx. D/C higher w/ PDE4i & poorer baseline activity & PROs https://t.co/BhxAMtjsZV
Peter Nash
@drpnash
Schett : in vivo the future if it works, during LD aciclovir, co-trimoxazole, CAR-T expansion amount not associated with toxicity, 3 month no vaccination window, all tissues B cell depletion , naive b cells return APLAR Seoul 2026 #CART #RheumNow
Peter Nash
@drpnash
number of naive-like CAR-T infused associates with prolonged survival but highly variable APLAR Seoul 2026 #CAR-T #Rheum Now
Peter Nash
@drpnash
lymphodepletion depends on individual cytokine profile and fludarabine PK effects efficacy APLAR Seoul 2026 #CAR-T #Rheum Now
×